The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
EGFR inhibitors are widely used to treat metastatic NSCLC; however, they can cause various adverse effects that differ from those caused by traditional intravenous chemotherapy.
Measuring levels of the molecule microRNA-31 might accurately determine if a patient's lung cancer has spread to nearby lymph nodes.
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Palliative Cancer Care Should Focus on Symptoms, Not Diagnoses
- COX-2 Inhibitors Can Improve Response to Immunotherapy of Some Cancer Tumors
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|